Zenagamtide (amycretin)
A single-molecule GLP-1 and amylin receptor agonist studied in injectable and oral formulations.
Evidence-led profile
Research snapshot
- Evidence stage
- Investigational; early-phase human obesity research
- References
- 1 linked sources
- Research coverage
- 1 area
- Editorial review
- Sep 30, 2026
Published by the PepGuide Editorial Team using our research methodology.
Overview
The published injectable phase 1b/2a trial randomized 125 adults with overweight or obesity and no diabetes. The 60 mg cohort had an estimated mean weight change of −24.3% at week 36 versus −1.1% with placebo. The trial was small, included multiple dose cohorts and withdrawals, and was not a head-to-head comparison with semaglutide or tirzepatide. Oral and injectable formulations require separate evidence review.
Research
Human weight-management evidence
In 125 randomized adults without diabetes, an injectable 60 mg cohort had estimated mean weight change of −24.3% at 36 weeks versus −1.1% placebo. This is an early-phase, cohort-specific result and cannot be ranked against separate phase 3 trials. Original trial.
Safety and Limitations
The early trial reported gastrointestinal adverse events. A phase 1b/2a study cannot define long-term safety, rare harms, pregnancy risk, or a licensed clinical regimen. Zenagamtide had no FDA-approved U.S. product identified at this review.
Mechanism of Action
Single-molecule agonism at GLP-1 and amylin receptors; the clinical contribution of each pathway cannot be isolated from the published combination study.
References (1)
Continue researching Zenagamtide (amycretin)
Keep scientific evidence separate from commercial availability. Review how claims are evaluated, explore question-led research paths, or inspect disclosed source records without changing the editorial conclusions on this page.